DRTS

Alpha Tau Medical Ltd.

3.20 USD

Last updated Dec 8, 15:49 UTC

Yesterday HIGH

$3.2

Yesterday LOW

$3.05

52w HIGH

$5.95

52w LOW

$2.75

EPS

-0.07

PE

-45.71

Next Earnings

Mar 7, 2024

Overview News Government Trades

Alpha Tau Medical Ltd. stock is up 2.89% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.

N/A

Stock Exchange

-

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

-

Website

alphatau.com

Benzinga Insights

Wed Aug 16, 2023

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Tue Jul 25, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
richadhand@benzinga.com

Wed May 24, 2023

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Benzinga Insights

Tue May 23, 2023

Recap: Alpha Tau Medical Q1 Earnings
Happy Mohamed

Tue May 23, 2023

Alpha Tau Medical Q1 EPS $(0.12) Misses $(0.11) Estimate

Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 77.78 percent increase over losses of $(0.54) per share
richadhand@benzinga.com

Thu May 18, 2023

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Happy Mohamed

Wed May 17, 2023

Alpha Tau Expands Its Alpha DaRT Treatment To Vulvar Cancer In Novel Clinical Trial With Cambridge University

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient
richadhand@benzinga.com

Mon May 15, 2023

HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $9 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $9 price target.
Happy Mohamed

Thu May 11, 2023

Alpha Tau Announces The Publication Of Its US Multicenter Pilot Skin Cancer Trial Results In JAMA Network Open

The trial demonstrated a 100% Complete Response rate at 12 weeks post treatment and no device-related serious adverse events or systemic toxicity reported in the 10 patients treated in the feasibility and
Benzinga Insights

Mon Apr 24, 2023

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023

HC Wainwright & Co.

Mon Nov 20, 06:11

buy

confirm
Piper Sandler

Fri Nov 17, 12:14

buy

confirm